233 related articles for article (PubMed ID: 18776915)
1. CGRP blockers in migraine therapy: where do they act?
Edvinsson L
Br J Pharmacol; 2008 Dec; 155(7):967-9. PubMed ID: 18776915
[TBL] [Abstract][Full Text] [Related]
2. CGRP receptor antagonism and migraine.
Edvinsson L; Ho TW
Neurotherapeutics; 2010 Apr; 7(2):164-75. PubMed ID: 20430315
[TBL] [Abstract][Full Text] [Related]
3. CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?
Walker CS; Hay DL
Br J Pharmacol; 2013 Dec; 170(7):1293-307. PubMed ID: 23425327
[TBL] [Abstract][Full Text] [Related]
4. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
Chen ST; Wu JW
Prog Brain Res; 2020; 255():123-142. PubMed ID: 33008504
[TBL] [Abstract][Full Text] [Related]
5. CGRP receptor antagonism and migraine therapy.
Edvinsson L; Warfvinge K
Curr Protein Pept Sci; 2013 Aug; 14(5):386-92. PubMed ID: 23745702
[TBL] [Abstract][Full Text] [Related]
6. Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288.
Knight YE; Edvinsson L; Goadsby PJ
Neuropeptides; 1999 Feb; 33(1):41-6. PubMed ID: 10657470
[TBL] [Abstract][Full Text] [Related]
7. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.
Edvinsson L; Warfvinge K
Cephalalgia; 2019 Mar; 39(3):366-373. PubMed ID: 29020807
[TBL] [Abstract][Full Text] [Related]
8. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.
Goadsby PJ
Drugs; 2005; 65(18):2557-67. PubMed ID: 16392873
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
Yuan H; White CS; Silberstein SD
Clin Pharmacol Ther; 2019 May; 105(5):1121-1129. PubMed ID: 30648737
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine.
Messlinger K; Fischer MJ; Lennerz JK
Keio J Med; 2011; 60(3):82-9. PubMed ID: 21979827
[TBL] [Abstract][Full Text] [Related]
12. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system.
Link AS; Kuris A; Edvinsson L
J Headache Pain; 2008 Feb; 9(1):5-12. PubMed ID: 18217201
[TBL] [Abstract][Full Text] [Related]
13. [Neuropeptide effects on the trigeminal system: pathophysiology and clinical significance for migraine].
Messlinger K; Fischer MJ; Lennerz JK
Schmerz; 2011 Aug; 25(4):393-8, 400-1. PubMed ID: 21818718
[TBL] [Abstract][Full Text] [Related]
14. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
Edvinsson L; Haanes KA; Warfvinge K; Krause DN
Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
[TBL] [Abstract][Full Text] [Related]
15. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
Villalón CM; Olesen J
Pharmacol Ther; 2009 Dec; 124(3):309-23. PubMed ID: 19796656
[TBL] [Abstract][Full Text] [Related]
16. CGRP mechanism antagonists and migraine management.
Karsan N; Goadsby PJ
Curr Neurol Neurosci Rep; 2015 May; 15(5):25. PubMed ID: 25790955
[TBL] [Abstract][Full Text] [Related]
17. CGRP receptors in the control of pain and inflammation.
Benemei S; Nicoletti P; Capone JG; Geppetti P
Curr Opin Pharmacol; 2009 Feb; 9(1):9-14. PubMed ID: 19157980
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin gene-related peptide: an update on the biology.
Recober A; Russo AF
Curr Opin Neurol; 2009 Jun; 22(3):241-6. PubMed ID: 19434786
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin gene-related peptide and its role in migraine pathophysiology.
Arulmani U; Maassenvandenbrink A; Villalón CM; Saxena PR
Eur J Pharmacol; 2004 Oct; 500(1-3):315-30. PubMed ID: 15464043
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
